Lateral Flow Strip

Megananodiagnostic Inc. Overview

Megananodiagnostic Inc., based at the University of South Florida’s Tampa campus, is a startup founded by a team of experts in neuroimmunology, pharmacology, biology, and biostatistics. The company specializes in peptide design, antibody services, and the development of detection kit, with a focus on rapid diagnostic assays for neurological diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD).

The Challenge

Current biomarker tests for AD and PD require patients to visit clinics for blood draws, with samples sent off-site for analysis. This process takes at least a week, is costly, and is impractical for frequent monitoring. As a result, patients often miss the critical window for effective treatment.

Our Solution

Megananodiagnostic Inc. has developed two innovative lateral flow assays (pending patent) that address these challenges:

Assay 1: Detects oligomeric amyloid beta and p-tau217 in a single strip.
Assay 2: Detects aggregated alpha-synuclein, oligomeric amyloid beta, amyloid beta 42, and amyloid beta 40 in one strip.

These assays enable the simultaneous detection of multiple biomarkers from a single sample, allowing fast and cost-effective testing without specialized equipment. Additionally, we’ve created a user-friendly, quantifiable tool for at-home monitoring, empowering patients to track biomarker changes over time.

About the App

To complement our lateral flow assays, we have developed a web-based tool designed with simplicity and accessibility in mind.

Easy to use: Users can quickly create an account, log in, and upload images of their test strips, guided by step-by-step visual prompts for accurate capture.
Instant results: The system processes each image to generate clear, quantified results, displayed in the user’s personal results section.
Personal dashboard: Users can view their most recent test, explore a full history of past results, and update their personal information at any time.

By combining an intuitive design with advanced image analysis, the app empowers individuals to track their biomarkers over time in a way that is convenient, reliable, and easy to use at home.

Open the App

Impact

Our lateral flow assays enable:

Early Detection: Older adults can monitor AD and PD biomarkers at home, allowing for early detection and improved treatment outcomes.
Preventive Monitoring: Younger individuals can establish baseline biomarker levels and track changes to identify risk factors and prevent disease progression.
Precision Medicine: The assays support disease stratification for personalized treatment plans.

Megananodiagnostic Inc. is committed to revolutionizing neurological disease diagnostics, making testing accessible, affordable, and actionable for all.